C

Compass Oncology | Vancouver, WA

Research site

(Unclaimed)

Location

1498 Tech Center Place, Suite 240, Vancouver, Washington, United States of America

Site insights

Top conditions

Top treatments

MSB0011359C

Demcizumab

Platinum

M7824

Carboplatin

Osimertinib

NUC-3373

Lazertinib

Amivantamab

Nilotinib

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

4 of 8 total trials

A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure (MARIPOSA-2)

The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) a...

Active, not recruiting

Carcinoma, Non-Small-Cell Lung

Drug: Pemetrexed

Drug: Carboplatin

Phase 3 Clinical Study of AK112 for NSCLC Patients

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Active, not recruiting

Non-Squamous Non-small Cell Lung Cancer

Drug: Placebo Injection

Drug: Ivonescimab (SMT112 or AK112) Injection

Phase III Study of AK112 for NSCLC Patients

A Randomized, Double-blind, Multi-center, Phase III Clinical Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR...

Active, not recruiting

Non-Squamous Non-small Cell Lung Cancer

Drug: Placebo Injection

Drug: AK112 Injection

Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)

A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in chronic myeloid leukemia (CML) patients. Patients who sta...

Active, not recruiting

Chronic Myeloid Leukemia

Drug: nilotinib